NASDAQ:MYOK - Myokardia Stock Price, Price Target & More Sign in or create an account to add this stock to your watchlist. Get Started $55.75 +0.10 (+0.18 %) (As of 07/17/2018 05:51 AM ET)Previous Close$55.65Today's Range$54.70 - $55.9052-Week Range$13.10 - $62.83Volume237,700 shsAverage Volume416,290 shsMarket Capitalization$2.00 billionP/E Ratio-39.82Dividend YieldN/ABeta3.54 Company ProfileFinancialsAnalyst RatingsEarnings HistoryInsider TradesHeadlinesOptions ChainSEC FilingsSocial MediaChart Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email MyoKardia, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of rare cardiovascular diseases. Its lead product candidate is mavacamten, an orally administered small molecule, which has completed Phase II clinical trial that is designed to reduce left ventricular contractility to potentially alleviate the functional consequences and symptoms of hypertrophic cardiomyopathy (HCM) and prevent or reverse HCM progression. The company also develops MYK-491, an orally-administered small molecule, which is in Phase I b clinical trial that is designed to restore normal contractility in the diseased dilated cardiomyopathy (DCM) heart. Its three preclinical programs include HCM-2 that is used to reduce cardiac muscle contractility to normal levels in HCM patients; DCM-2, which is used to enhance cardiac muscle contractility to normal levels in genetic DCM patients; and LUS-1 that is used to counteract a muscle disruption that results in impaired relaxation of the heart, a biomechanical defect found in specific HCM and genetic DCM patient subgroups, as well as in other less common heritable cardiomyopathies. The company has a strategic collaboration with Aventis Inc. for the research, development, and commercialization of pharmaceutical products to treat, prevent, and diagnose HCM and DCM, as well as additional indications. MyoKardia, Inc. was founded in 2012 and is headquartered in South San Francisco, California. Receive MYOK News and Ratings via Email Sign-up to receive the latest news and ratings for MYOK and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical SymbolNASDAQ:MYOK CUSIPN/A Webwww.myokardia.com Phone650-741-0900 Debt Debt-to-Equity RatioN/A Current Ratio4.63 Quick Ratio4.63 Price-To-Earnings Trailing P/E Ratio-39.82 Forward P/E Ratio-27.06 P/E GrowthN/A Sales & Book Value Annual Sales$22.50 million Price / Sales89.13 Cash FlowN/A Price / CashN/A Book Value$6.76 per share Price / Book8.25 Profitability EPS (Most Recent Fiscal Year)($1.40) Net Income$-45,950,000.00 Net Margins-235.47% Return on Equity-25.18% Return on Assets-20.76% Miscellaneous Employees102 Outstanding Shares35,970,000Market Cap$2,001.51 Myokardia (NASDAQ:MYOK) Frequently Asked Questions What is Myokardia's stock symbol? Myokardia trades on the NASDAQ under the ticker symbol "MYOK." How were Myokardia's earnings last quarter? Myokardia Inc (NASDAQ:MYOK) posted its earnings results on Tuesday, May, 8th. The biotechnology company reported ($0.50) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.29) by $0.21. The biotechnology company had revenue of $5.33 million for the quarter, compared to analyst estimates of $7.82 million. Myokardia had a negative net margin of 235.47% and a negative return on equity of 25.18%. View Myokardia's Earnings History. What price target have analysts set for MYOK? 7 Wall Street analysts have issued 12 month price objectives for Myokardia's stock. Their forecasts range from $54.00 to $83.00. On average, they expect Myokardia's share price to reach $69.7143 in the next year. This suggests a possible upside of 25.0% from the stock's current price. View Analyst Ratings for Myokardia. What is the consensus analysts' recommendation for Myokardia? 7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Myokardia in the last year. There are currently 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." Who are some of Myokardia's key competitors? Some companies that are related to Myokardia include SAGE Therapeutics (SAGE), Alkermes (ALKS), Catalent (CTLT), Ionis Pharmaceuticals (IONS), Dr.Reddy's Laboratories (RDY), United Therapeutics (UTHR), Loxo Oncology (LOXO), FibroGen (FGEN), Agios Pharmaceuticals (AGIO), GALAPAGOS NV/S (GLPG), Ligand Pharmaceuticals (LGND), Taro Pharmaceutical Industries (TARO), Madrigal Pharmaceuticals (MDGL), GW Pharmaceuticals (GWPH) and HUTCHISON CHINA/S (HCM). Who are Myokardia's key executives? Myokardia's management team includes the folowing people: Mr. Tassos Anastasios Gianakakos, Pres, CEO & Director (Age 45)Dr. June Lee, COO & Chief Devel. Officer (Age 52)Dr. Robert S. McDowell, Chief Scientific Officer (Age 60)Dr. Charles J. Homcy, Advisor (Age 70)Dr. Eric J. Topol, Advisor (Age 64) Has Myokardia been receiving favorable news coverage? Media coverage about MYOK stock has trended somewhat negative recently, Accern Sentiment reports. The research group scores the sentiment of media coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Myokardia earned a daily sentiment score of -0.04 on Accern's scale. They also assigned news coverage about the biotechnology company an impact score of 43.63 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company's share price in the next several days. Who are Myokardia's major shareholders? Myokardia's stock is owned by many different of institutional and retail investors. Top institutional shareholders include Handelsbanken Fonder AB (0.15%) and Xact Kapitalforvaltning AB (0.02%). Company insiders that own Myokardia stock include Anastasios Gianakakos, Jake Bauer, Joseph Lambing, Kevin P Starr, Rock Ventures Ii LP Third, Sanofi and Wendy L Yarno. View Institutional Ownership Trends for Myokardia. Which institutional investors are buying Myokardia stock? MYOK stock was acquired by a variety of institutional investors in the last quarter, including Handelsbanken Fonder AB and Xact Kapitalforvaltning AB. Company insiders that have bought Myokardia stock in the last two years include Sanofi and Wendy L Yarno. View Insider Buying and Selling for Myokardia. How do I buy shares of Myokardia? Shares of MYOK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Myokardia's stock price today? One share of MYOK stock can currently be purchased for approximately $55.75. How big of a company is Myokardia? Myokardia has a market capitalization of $2.00 billion and generates $22.50 million in revenue each year. The biotechnology company earns $-45,950,000.00 in net income (profit) each year or ($1.40) on an earnings per share basis. Myokardia employs 102 workers across the globe. How can I contact Myokardia? Myokardia's mailing address is 333 ALLERTON AVENUE, SOUTH SAN FRANCISCO CA, 94080. The biotechnology company can be reached via phone at 650-741-0900 or via email at [email protected] MarketBeat Community Rating for Myokardia (NASDAQ MYOK)Community Ranking: 2.4 out of 5 ( )Outperform Votes: 142 (Vote Outperform)Underperform Votes: 148 (Vote Underperform)Total Votes: 290MarketBeat's community ratings are surveys of what our community members think about Myokardia and other stocks. Vote "Outperform" if you believe MYOK will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MYOK will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 7/17/2018 by MarketBeat.com StaffFeatured Article: Are analyst ratings accurate?